Accuray downgraded to Underweight from Neutral at JPMorgan JPMorgan downgraded Accuray to Underweight after the company pre-announced Q2 results that dramatically missed expectations. The firm believes a company turnaround, if possible, is a multi-year process.
Accuray says 16 hospitals in China awarded class A user licenses Accuray announced earlier today that class A user licenses for Accuray products were awarded to 16 hospitals during February by the Chinese National Health and Family Planning Commission. TomoTherapy System licenses were received by 12 hospitals and CyberKnife System licenses were received by four hospitals. Of the 16 licenses just issued, Accuray believes that six licenses will allow orders already in backlog to be recognized as revenue in the near future and 10 licenses are expected to lead to new system orders entered into backlog in the coming months. In total, between 2013 and year to date 2015, the NHFPC has released 32 of its planned 60 licenses.